Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Psychiatric Disorder, Drug Use
Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users
The main objective of this study is to show that People Who Inject Drugs (PWID) suffering initially from a major depressive disorder, a psychotic disorder and/or had a suicide risk and who received a community-based psychiatric…
- Trial name
- DRIVEMINDII (NCT05886504)
- Testing
- Community-based psychiatric intervention
- Where
- Vietnam
- Volunteers
- 567 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
This trial is evaluating a public health intervention strategy trial which aims to reduce the incidence of HIV at a population-level.
- Trial name
- TasP (NCT01509508)
- Testing
- Immediate ARV treatment initiation with TDF/FTC/EFV, South African recommendation guided ARV (TDF/FTC/EFV) initiation
- Where
- South Africa
- Volunteers
- 28,153 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Chronic
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients.
- Trial name
- Fibrosar (NCT00265642)
- Testing
- Irbesartan
- Where
- France
- Volunteers
- 166 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone
The main objective of the study is to characterize the diffusion of dolutegravir and associated backbone (abacavir/lamivudine or tenofovir/emtricitabine) in HIV-1 chronic patients in the main putative reservoirs, namely inguinal…
- Trial name
- DOLUVOIR (NCT04133012)
- Testing
- Samplings
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C Virus Genotype 4 Infection
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Success rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard treatment, are disappointing.
- Trial name
- NCT02107365
- Testing
- Asunaprevir, Daclatasvir, Ribavirin
- Where
- 25 sites in France
- Volunteers
- 60 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV…
- Trial name
- QUATUOR (NCT03256422)
- Testing
- Treatment discontinuation
- Where
- 63 sites in France
- Volunteers
- 640 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection, Chronic Renal Insufficiency
Renal Transplantation and Raltegravir in HIV-Infected Patients
The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
- Trial name
- ANRS153TREVE (NCT01453192)
- Testing
- Raltegravir
- Where
- 14 sites in France
- Volunteers
- 27 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers
The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers.
- Trial name
- EV03/ANRSVAC20 (NCT00490074)
- Testing
- DNA-C, NYVAC-C
- Where
- 2 sites in France, Switzerland
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Maternal-fetal Infection Transmission
Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors
The overall goal is to study the feasibility of darunavir/ritonavir (DRV/r) monotherapy as treatment simplification (switch) in pretreated pregnant women, associated with neonatal prophylaxis with nevirapine, constituting a PMTCT…
- Trial name
- MONOGEST (NCT02738502)
- Testing
- darunavir monotherapy
- Where
- 23 sites in France
- Volunteers
- 91 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection
The purpose of this study is to compare the impact of two combination of two tablets once daily: dolutegravir associated with emtricitabine / tenofovir versus darunavir / cobicistat associated with emtricitabine / tenofovir on…
- Trial name
- OPTIPRIM-2 (NCT02987530)
- Testing
- Dolutegravir, Darunavir-cobicistat, Emtricitabine-Tenofovir
- Where
- France
- Volunteers
- 101 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis B, HIV Infection
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)
HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer.
- Trial name
- B-BOOST (NCT00670839)
- Testing
- GenHevac-B
- Where
- France
- Volunteers
- 178 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults
The primary objective of the trial is to assess the ability of an early and intermittent antiretroviral therapy in maintaining an immunological stability in antiretroviral naive HIV infected adults, to offer a potential…
- Trial name
- TIPI (NCT00820118)
- Testing
- Structured treatment interruption
- Where
- France
- Volunteers
- 45 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva
In the pre-partum phase the use of antiretroviral therapy for the mother during the last trimester of pregnancy is mandatory. The use of HAART during pregnancy, usually two nucleosides analogues and a protease inhibitor exposes…
- Trial name
- NCT00424814
- Testing
- Kaletra (lopinavir/ritonavir), Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
the ANRS CO21 " Extreme " Cohort (CODEX)
A consortium of research teams has studied the immunovirological characteristics of these patients: The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
- Trial name
- CODEX (NCT01520844)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 450 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Unsafe Sex, Risk-Taking
Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)
The study ANRS 174 Doxyvac is a clinical trial that will use Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men and using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) and…
- Trial name
- DOXYVAC (NCT04597424)
- Testing
- Experimental: doxycycline, Bexsero® vaccine
- Where
- 9 sites in France
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
In HIV infected patients, individuals exposed to the virus of Hepatitis B are more susceptible to develop a chronic and severe liver disease with a major risk of cirrhosis and liver cancer.
- Trial name
- VIHVAC-B (NCT00480792)
- Testing
- GenHevac B Pasteur
- Where
- France
- Volunteers
- 437 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis
ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV
The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months.
- Trial name
- ETOC (NCT00901524)
- Testing
- Peg-interféron alpha 2a + ribavirin
- Where
- France
- Volunteers
- 58 people
- Sponsor
- ANRS, Emerging Infectious Diseases